4.5 Article

Systematic Immunohistochemical Analysis of the Expression of CD46, CD55, and CD59 in Colon Cancer

期刊

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
卷 138, 期 7, 页码 910-919

出版社

COLL AMER PATHOLOGISTS
DOI: 10.5858/arpa.2013-0064-OA

关键词

-

资金

  1. National 973 Project [2010CB529300, 2010CB529302, 2010CB529305, 2010CB529306]
  2. National 863 Project [2012AA02A203, 2012AA02A504]
  3. National Natural Science Foundation of China [81120108005, 81030044, 30970149, 30900675, 81227901]

向作者/读者索取更多资源

Context.-The expression of membrane-bound complement regulatory proteins (mCRPs) that inhibit the complement system in normal tissues is essential for self-protection against an autologous immune reaction. However, the expression patterns of mCRPs, including CD46, CD55, and CD59, are inconsistent in different types of cancer cells. Objectives.-To determine whether CD46, CD55, and CD59 are differentially expressed in neoplastic and adjacent normal colon tissues and to assess their clinical significance. Design.-Immunohistochemistry was performed on tissue microarrays of cancerous and adjacent normal colon tissues. Results.-The expression levels of CD46, CD55, and CD59 were significantly higher in colon cancer tissues compared with the normal adjacent colon tissues. We found that the expression levels of CD55 and CD59 correlated with the grade of differentiation in colon cancers. In addition, the expression of CD55 and CD59 was greater in stage III and stage IV colon cancers than in stage I and stage II cancers according to staging by the TNM classification. Conclusions.-CD46, CD55, and CD59 are up-regulated in colon cancer. Specifically, CD55 and CD59 are of clinical relevance to differentiation and TNM staging of colon cancer. These data suggest that CD46, CD55, and CD59 have the potential to be used for molecular staging diagnoses and for colon cancer therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据